scholarly journals Integration with Spilanthes Achmella in fibromyalgia syndrome: open-label study six months after the treatment

2021 ◽  
Vol 3 (3) ◽  
Author(s):  
Marco Bardelli ◽  
Stefano Gentileschi ◽  
Bruno Frediani ◽  
Maurizio Benucci

Fibromyalgia, also known as fibromyalgia syndrome (FM), is a rheumatic syndrome which is currently considered idiopathic and multifactorial. It causes an increase in muscle tension associated with stiffness, asthenia (loss of strength with fatigue), cognitive impairment, insomnia or sleep disorders and impaired sensitivity to stimuli. We performed a prospective evaluation of 149 patients suffering from fibromyalgia syndrome according to the 2010 ACR Criteria. Patients were clinically assessed at baseline and after 1-3-6 months, using the patient-reported outcomes thermometer - 5-item scale (5TPROs). In addition to their therapy, all patients received a supplementation with Spilanthes Achmella. This food supplement is characterized by synergy of bioactive compounds, such as Acmella oleracea extract, and has neurotrophic, anti-inflammatory and pain-relieving effects. All patients were randomized at baseline to receive Spilanthes Achmella, 2 tablets per day for one month and subsequent tapering to 1 tablet per day for 5 months. At six months, a statistically significant difference in the following parameters was shown: pain P<0.001, fatigue P<0.001, physical function P<0.001, depression: P<0.001, general health P<0.001. Conversely, the post-hoc analysis data did not report any significant difference for the parameters between the third and sixth month. A drug-sparing effect was observed (P<0.001). The posthoc analysis revealed a significant difference between T0 and T3 P=0.00066 and between T0 and T6 P=0.00008. Our data indicate that supplementation with Spilanthes Achmella may lead to a significant improvement in pain, fatigue, physical function, depression and general health in fibromyalgia syndrome.

2018 ◽  
Vol 6 (5) ◽  
pp. 232596711877450 ◽  
Author(s):  
Elizabeth J. Scott ◽  
Robert Westermann ◽  
Nathalie A. Glass ◽  
Carolyn Hettrich ◽  
Brian R. Wolf ◽  
...  

Background: The Patient-Reported Outcomes Measurement Information System (PROMIS) is designed to advance patient-reported outcome (PRO) instruments by utilizing question banks for major health domains. Purpose: To compare the responsiveness and construct validity of the PROMIS physical function computer adaptive test (PF CAT) with current PRO instruments for patients before and up to 2 years after anterior cruciate ligament (ACL) reconstruction. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Initially, 157 patients completed the PROMIS PF CAT, Short Form–36 Health Survey (SF-36 physical function [PF] and general health [GH]), Marx Activity Rating Scale (MARS), Knee injury and Osteoarthritis Outcome Score (KOOS activities of daily living [ADL], sport, and quality of life [QOL]), and EuroQol–5 dimensions questionnaire (EQ-5D) at 6 weeks, 6 months, and 2 years after ACL reconstruction. Correlations between instruments, ceiling and floor effects, effect sizes (Cohen d), and standardized response means to describe responsiveness were evaluated. Subgroup analyses compared participants with and without additional arthroscopic procedures using linear mixed models. Results: At baseline, 6 weeks, and 6 months, the PROMIS PF CAT showed excellent or excellent-good correlations with the SF-36 PF ( r = 0.75-0.80, P < .01), KOOS-ADL ( r = 0.63-0.70, P < .01), and KOOS-sport ( r = 0.32-0.69, P < .01); excellent-good correlation with the EQ-5D ( r = 0.60-0.71, P < .01); and good correlation with the KOOS-QOL ( r = 0.52-0.58, P < .01). As expected, there were poor correlations with the MARS ( r = 0.00-0.24, P < .01) and SF-36 GH ( r = 0.16-0.34, P < .01 ). At 2 years, the PROMIS PF CAT showed good to excellent correlations with all PRO instruments ( r = 0.42-0.72, P < .01), including the MARS ( r = 0.42, P < .01), indicating frequent return to preinjury function. The PROMIS PF CAT had the fewest ceiling or floor effects of all instruments tested, and patients answered, on average, 4 questions. There was no significant difference in baseline physical function scores between subgroups; at follow-up, all groups showed improvements in scores that were not statistically different. Conclusion: The PROMIS PF CAT is a valid tool to assess outcomes after ACL reconstruction up to 2 years after surgery, demonstrating the highest responsiveness to change with the fewest ceiling and floor effects and a low time burden among all instruments tested. The PROMIS PF CAT is a beneficial alternative for assessing physical function in adults before and after ACL reconstruction.


2019 ◽  
Vol 7 (3_suppl) ◽  
pp. 2325967119S0015
Author(s):  
Matthew J. Brown ◽  
Lauren Agatstein ◽  
Brian Haus ◽  
Joel Lerman

BACKGROUND Fibular deficiency is a common long-bone deficiency with an estimated incidence of 7.4-20 cases per million live births. Absence or hypoplasia of the cruciate ligaments is present in most patients with fibular deficiency. In one series, the anterior cruciate ligament (ACL) was deficient in 95% while the posterior cruciate ligament (PCL) was deficient in 60% of patients with fibular deficiency. Symptomatic instability of the knee is variably present in patients with congenital absence of the ACL including fibular deficiency, with a reported incidence of between 3% and 50%. Despite this reported incidence, limited literature assessing the perceived knee stability in patients with fibular deficiency exists. METHODS Patients diagnosed with fibular hemimelia with congenital absence of the ACL were identified retrospectively at a pediatric hospital. Of the identified patients over the age of 16, 28 agreed to be part of the study and were sent an online survey. They completed Lysholm and Patient-Reported Outcomes Measurement Information System (PROMIS) surveys on knee problems, physical function, pain intensity, and overall health. The PROMIS raw score responses were converted to a T-score, scaled to a mean of 50 points (representative of the mean of the reference population), with a standard deviation of 10 points. Any response more than one standard deviation away from 50 was considered worthy of further review. 18 patients returned surveys, and these individuals comprise the final study group. RESULTS Of the study patients, the average age was 19.8 years (16-24 years), with 7 females and 11 males. 9 patients are amputees and 9 are non-amputees. On the Lysholm Knee Scoring Scale, the highest possible score is 100 points, which relates to normal knee function. Our average Lysholm score was 79.94, with a wide range in scores from 25-100 points, in comparison to the average adult knee score of 94 (Briggs et al). The amputee average Lysholm score was 77.8 and the non-amputee average Lysholm score was 74.1, with no statistically significant difference. For our cohort, the mean Physical Function T-score was 52 (range 27.5-60.1), with a higher score relating to better physical function. The amputee average score was 53.1 and the non-amputee average score was 45.8, with no statistically significant difference. 12 respondents reported normal physical function compared to the general population, with 8 more than 1 standard deviation (SD) above a T-score of 50. Of the 6 respondents with a physical function score lower than 50, 4 reported mild functional impairment (.5 – 1.0 SD), 1 moderate impairment (1.6 SD), and 1 severe impairment (2.25 SD). The severe impairment was reported by an amputee and the moderate physical impairment reported by a non-amputee. For the PROMIS Global Physical Health domain, the mean T-score was 52.6 (range 29 -63.3). There was no significant difference between the average scores of the amputee (54.8) and non-amputee (50.3) groups. 13 respondents had no difference or had better health than the normal population mean, with 8 being amputees and 5 being non-amputees. 5 respondents had the highest possible score of 63.3, which is 1.33 standard deviations better than the normal average (2 non-amputees and 3 amputees). Of the 5 patients (4 non-amputees and 1 amputee) reporting worse health, only 1 respondent reported severe health impairments (2.1 SD). All PROMIS subject areas measure whether more of the domain occurs. For Physical Function and Global Health, a higher score indicates improved function. In the Pain Intensity realm, a higher score relates to more pain. In this study population, the mean pain T-score was 40.15 (range 30.7 – 60.5). The amputee average score was 38.98 and the non-amputee average score was 41.3, with no significant difference between them. 16 patients had less pain or normal pain levels compared to the population mean. Of the two patients reporting worse pain than the normal population, the amputee patient had mild pain (within 1 SD of 50) and the non-amputee had moderate pain (1.05 SD). CONCLUSIONS The only previously published report on knee function in adults with fibular deficiency contained 11 patients; our 18 patients substantially expands data available on knee function in these patients. Previously, Crawford, et al, obtained Lysholm and Musculoskeletal Outcomes Data Evaluation and Management System (MODEMS) scores on nine patients treated since 1928. Their data demonstrated an average Lysholm score of 90.2, compared to ours of 79.94. The majority of our patients demonstrated excellent PROMIS responses, with 12-15 demonstrating average or above pain, physical function, and global health scores. Amputees tended to self-report better health than the non-amputees. Overall, in the young adult cohort, we demonstrate that the majority of patients with fibular deficiency function well and have a stable knee, although a small subset of patients do have challenges with knee function.


2020 ◽  
Vol 5 (4) ◽  
pp. 2473011420S0038
Author(s):  
Charles C. Pitts ◽  
Bradley Alexander ◽  
Elise M. Greco ◽  
Benjamin B. Cage ◽  
Spaulding F. Solar ◽  
...  

Category: Other; Ankle; Ankle Arthritis; Bunion; Hindfoot; Lesser Toes; Midfoot/Forefoot Introduction/Purpose: The Patient-Reported Outcomes Measurement Instrumentation System (PROMIS) has become increasingly utilized in orthopaedic foot and ankle surgery to assess outcomes and better understand patient function, pain, and disability. Similarly, the Foot Function Index (FFI) is used to assess pain, disability, and activity limitation. PROMIS scores have been shown to predict, preoperatively, which patients will benefit most from foot and ankle surgery from a general perspective. It is currently unknown, with regard to chronic foot pathology, which region of the foot has the greatest effect on PROMIS and FFI scores and which region is affected the most by surgical intervention. Methods: PROMIS physical function, pain index, and depression scores along with FFI scoring subsets of pain, disability, and activity limitation were retrospectively reviewed for patients at a tertiary referral center with chronic pathology in either the hindfoot, midfoot, or forefoot that underwent surgery. Scores were obtained preoperatively and at 6 weeks postoperatively, and a preoperative to postoperative difference was calculated. Once the mean of each subcategory was obtained, an analysis of variance (ANOVA) was conducted in order to compare the means and identify statistically significant differences. Significance was set at p < 0.05 and p < 0.10. Results: There was no statistically significant difference between the mean preoperative PROMIS or FFI scores in the forefoot, midfoot, or hindfoot regions. There was also no statistically significant difference between means of PROMIS or FFI categories at 6 weeks postoperatively. However, the mean pre- to postoperative differences between PROMIS physical function scores of the forefoot, midfoot, and hindfoot were statistically significantly different at 9.12, 8.16, and 2.88, respectively (p=0.037). There was no statistically significant difference between the remaining scoring categories. Conclusion: Physical function, pain, depression, disability, and activity limitation are not affected disparately by the location of chronic pathology within the foot. Surgical intervention for problems in the forefoot, midfoot, and hindfoot does not provide differences in outcomes with regard to pain, disability, depression, or activity limitation based on region. Patients who have undergone surgical intervention for forefoot or midfoot pathology may experience greater improvements in physical function postoperatively when compared to patients who have undergone hindfoot surgery. [Table: see text]


2020 ◽  
Vol 8 (7_suppl6) ◽  
pp. 2325967120S0039
Author(s):  
Shanthan Challa ◽  
Marissa Holliday ◽  
Kenneth Bartolomei ◽  
Jonathan Bartolomei

Objectives: Injuries are a major part of elite sports, and patient-reported outcomes tools (PROs) are becoming commonplace for the assessment of injury and treatment outcomes. The National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated set of assessment tools with increasing popularity. The PROMIS metrics utilize computerized adaptive testing (CAT) to capture health status measurements through individualized assessments, with minimal user burden, and without the loss of precision or content validity. The purpose of this study was to evaluate elite athletes using PROMIS scores and assess the impact of injury on those scores to gain insight into how participation and injury can impact the health of NCAA Division 1 athletes participating in a variety of sports. Methods: Over six months, athletes from 11 sports at a single Division 1 Athletics program were recruited to participate in longitudinal prospective data collection using four PROMIS CAT scales/domains: Pain Interference (PI), Physical Function (PF), Depression, and Ability to Participate in Social Roles and Activities (PSRA). Using REDCap (Research Electronic Data Capture), athletes completed an assessment that included the PROMIS tools before participation in their respective sport’s season for the 2018-2019 academic year and following the completion of their season. Athletes suffering a season-ending injury were asked to complete the PROMIS survey within a week following the injury. De-identified data was analyzed using Student’s T-test. PROMIS outcome measures were analyzed using linear mixed model regression. A p-value of < 0.05 was considered statistically significant. Results: A total of 592 surveys were collected, composed of 320 pre-season surveys, 241 post-season surveys, and 31 season altering injury surveys. PF, Depression, and PSRA scores were significantly different in athletes than in the general age-matched population (Fig 1). PI scores were similar to the normal population. The distribution of PI and PF scores were significantly different pre and post-season with a difference in means of 1.499 (p=0.030) and -2.019 (p=0.005), respectively. No significant difference was observed in the Depression and PSRA scores at the end of the season (Fig 1). A total of 31 significant injuries were reported. Injuries resulted in a significant change from pre-season to post-season scores amongst all participants (Fig 1). Conclusion: There were significantly worse pain interference and physical function scores post-season compared to preseason, suggesting that athletic participation alone may impact the athlete’s overall function and condition. Season-altering injuries resulted in clinically significant differences in all four domains, PI, PF, Depression, and PSRA, suggesting that injuries greatly affect athletes not only physically, but mentally and socially as well. Statistically significant changes were seen in depression and social metrics after injury compared to the athlete’s pre-season scores. Consideration should be given to index pre-season PROMIS scores for individual athletes to make follow-up scores athlete-specific, meaningful, and actionable. There is a clear need for additional investigation into the impact of specific sports and specific injuries, which would be valuable to trainers, coaches, and clinicians to inform treatment and return to sport protocols.


2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 134-134 ◽  
Author(s):  
Lynn Jackson Howie ◽  
Harpreet Singh ◽  
Bellinda King-Kallimanis ◽  
Jessica Roydhouse ◽  
Marc Robert Theoret ◽  
...  

134 Background: Patient-reported outcome measures (PROs) can capture the patient’s experience with disease and treatment. Anti-PD-1/PD-L1 therapies have unique symptomatic side effects; PRO data can help to better understand the patient experience on therapy. Health-related quality of life (HRQL) components most impacted by therapy include disease symptoms, symptomatic toxicity and physical function. Methods: We reviewed FDA registration trials for 5 immunotherapy agents (anti-PD-1/PD-L1) to evaluate trial design and PRO assessment. We assessed whether the PRO strategy assessed physical function and symptomatic immune-related adverse events (irAEs) by reviewing whether trials used a well-defined physical function domain and 8 symptoms related to irAEs reported in product labels (fatigue, diarrhea, cough, shortness of breath, musculoskeletal pain, rash, pruritis and fever). Results: Data from 25 trials across 7 disease types and 1 tumor agnostic indication were evaluated. Of these, 13 were randomized and 22 were open label. Eighteen of 25 contained PRO assessments and all 18 used > 1 instrument. The most common instruments were the EQ-5D (N = 17), followed by EORTC QLQ-C30 (N = 15). Disease-specific PRO tools were included in 8 trials (5 lung, 1 head and neck, 1 melanoma and 1 renal cell), consisting of modules or scales from EORTC (N = 5), FACIT (N = 2) or the Lung Cancer Symptom Scale (N = 1). Sixty percent of the trials (15/25) used an instrument that contained a well-defined physical function (PF) domain. No trial used a PRO strategy assessing all 8 selected symptoms related to irAEs. Conclusions: Collection of PRO data in anti-PD-1/PD-L1 trials submitted to FDA was variable, and did not consistently assess treatment related symptoms and physical function. Use of a HRQL tool with well-defined functional scales supplemented by item banks or libraries to incorporate symptoms associated with irAEs may improve understanding of the patient experience while receiving anti-PD-1/PD-L1 treatment. These data, along with other important clinical data such as hospitalizations, ER visits and supportive care medications can inform the benefit risk assessment for regulatory purposes.


2017 ◽  
Vol 27 (4) ◽  
pp. 397-402 ◽  
Author(s):  
Borys V. Gvozdyev ◽  
Leah Y. Carreon ◽  
Christopher M. Graves ◽  
Stephanie A. Riley ◽  
Katlyn E. McGraw ◽  
...  

OBJECTIVEPatient-reported outcomes (PROs) such as the Oswestry Disability Index (ODI) and EuroQol-5D (EQ-5D) are widely used to evaluate treatment outcomes following spine surgery for degenerative conditions. The goal of this study was to use the Charlson Comorbidity Index (CCMI) as a measure of general health status, for comparison with standard PROs.METHODSThe authors examined serial CCMI scores, complications, and PROs in 371 patients treated surgically for degenerative lumbar spine conditions who were enrolled in the Quality and Outcomes Database from a single center. The cohort included 152 males (41%) with a mean age of 58.7 years. Patients with no, minor, or major complications were compared at baseline and at 1 year postoperatively.RESULTSMinor complications were observed in 177 patients (48%), and major complications in 34 (9%). There were no significant differences in preoperative ODI, EQ-5D, or CCMI among the 3 groups. At 1 year, there was a significantly greater deterioration in CCMI in the major complication group (1.03) compared with the minor (0.66) and no complication groups (0.44, p < 0.006), but no significant difference in ODI or EQ-5D.CONCLUSIONSDespite equivalent improvements in PROs, patients with major complications actually had greater deterioration in their general health status, as evidenced by worse CCMI scores. Because CCMI is predictive of medical and surgical risk, patients who sustained a major complication now carry a greater likelihood of adverse outcomes with future interventions, including subsequent spine surgery. Although PRO scores are a key metric, they fail to adequately reflect the potential long-term impact of major perioperative complications.


2018 ◽  
Vol 36 (34_suppl) ◽  
pp. 40-40
Author(s):  
Sara Lauren Mann ◽  
Willem Hardie Collier ◽  
Dominik Ose ◽  
Shane Brogan ◽  
Anna Catherine Beck ◽  
...  

40 Background: The Karnofsky Performance Score (KPS) is an important prognostic indicator in cancer care. Additionally, patient-reported outcomes are increasingly incorporated into clinical care and are validated in cancer patients with the NIH’s Patient-Reported Outcomes Measurement Information System (PROMIS). However, little is known about the concordance of the provider-rated KPS and patient-rated PROMIS measures. Methods: Retrospective review of patients with advanced cancer who underwent implantation of an intrathecal pump for refractory pain. We compared KPS and PROMIS scores recorded within 1 week of each other. PROMIS scores included an average score and 3 domains: physical function, fatigue, and pain interference. We divided each measure into 3 previously-described categories (Functionally Independent, Needs Limited Assistance, and Functionally Dependent) and assessed categorical concordance within each measure. The association of patient-related demographic and clinical characteristics were analyzed with KPS–PROMIS concordance using chi-square and Mann-Whitney U tests. Results: 47 patients were included. The provider-rated KPS score consistently indicated a higher functional status compared to the patient-rated PROMIS average score and across all PROMIS domain scores. 40% of patients were rated “Functionally Dependent” using the average PROMIS score, compared to just 19.1% using the KPS, a statistically significant difference (p=0.042). We noted categorical concordance of 55.3% for PROMIS average score, 57.5% for physical function, 44.7% for fatigue and 42.7% for pain interference compared to KPS. We found no statistically significant associations between concordance and patient demographics or characteristics. Conclusions: Our results revealed a notably low concordance in functional status in advanced cancer patients between provider-rated KPS and patient-rated PROMIS measures. Provider-rated scores consistently indicated a higher overall performance status, in particular with measures of the lowest functional status. Additional work is needed to better understand the reasons for this lack of concordance and its implications for ongoing clinical decision-making.


2012 ◽  
Vol 39 (6) ◽  
pp. 1185-1191 ◽  
Author(s):  
MARK C. GENOVESE ◽  
CHENGLONG HAN ◽  
EDWARD C. KEYSTONE ◽  
ELIZABETH C. HSIA ◽  
JACQUELINE BUCHANAN ◽  
...  

Objective.To evaluate the effect of golimumab on physical function, general health, and fatigue in patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.Methods.In the multicenter, randomized, placebo-controlled GO-FORWARD study, 444 adults with active RA despite MTX received subcutaneous placebo + MTX (crossover to golimumab 50 mg at Week 24), golimumab 100 mg + placebo, golimumab 50 mg + MTX, or golimumab 100 mg + MTX every 4 weeks. Physical function and general health were assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI) and Physical and Mental Component Summary (PCS, MCS) scores of the Medical Outcomes Study Short Form-36 questionnaire (SF-36), respectively, through Week 52. Fatigue was measured through Week 24 using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire.Results.Mean improvements from baseline in HAQ-DI, SF-36 PCS, and FACIT-Fatigue scores (Weeks 14 and 24) were significantly greater for golimumab 50 mg + MTX and 100 mg + MTX versus placebo + MTX. Significantly greater proportions of patients treated with golimumab + MTX achieved clinically meaningful improvements from baseline to Weeks 14 and 24 in HAQ-DI, PCS, and FACIT-Fatigue scores. Mean improvements in SF-36 PCS (Week 14), MCS (Week 24), and FACIT-Fatigue (Weeks 14 and 24) scores were significantly greater for golimumab 100 mg + placebo versus placebo + MTX. Mean improvements from baseline in HAQ-DI, SF-36 PCS, and MCS scores through Week 24 were sustained through Week 52.Conclusion.Patients with active RA despite MTX had significant improvement in physical function, general health, and fatigue following golimumab + MTX therapy; improvements in physical function and general health were maintained through Week 52. (Clinical Trials Registration NCT00264550)


2019 ◽  
Vol 4 (4) ◽  
pp. 2473011419S0031
Author(s):  
Rusheel Nayak ◽  
Milap Patel ◽  
Anish Kadakia

Category: Hindfoot Introduction/Purpose: Patient Reported Outcomes Instrumentation System (PROMIS) pain interference (PI) and physical function (PF) scales were recently validated for foot & ankle surgery. Few studies have explored PROMIS in advanced posterior tibial tendon dysfunction (PTTD) surgery. We examined the change in PROMIS scores after PTTD reconstruction surgery and aimed to determine whether preoperative PROMIS scores, radiographic data, and demographic data can model and predict surgical improvement. Methods: PF and PI scores were prospectively obtained on 215 patients between November 2013 and May 2017. Of the 34 patients who had PTTD surgery, 25 patients were included with a minimum follow-up of 7-months (mean 21.8). Paired t-tests and multivariable linear regression models tested the difference in PROMIS scores pre- to postoperatively. Minimal clinically important differences (MCID) and receiver operator curve (ROC) analysis determined the accuracy of using preoperative scores in predicting postoperative change. The MCID for PROMIS PI and PF was defined as half of its respective standard deviation. Multivariable linear regressions with preoperative PROMIS scores, changes in radiographic imaging, and BMI were created to model change in PROMIS scores. Results: There was a significant difference in pre- to postoperative mean PI PROMIS scores (p = 0.0016, average change = -7.16). Mean PF scores improved postoperatively, but not significantly (p = .0595, average change = +4.17). Improvement in PI remained significant (p= 0.02) after adjusting for significant predictors (education level and diabetes status). Multivariable regression models utilizing preoperative PROMIS scores, radiographic variables, and BMI were unable to predict changes in PF and PI scores (p > 0.05). Using pre-determined MCID criteria, 68% achieved surgical success for PI (defined as change of at least -3.45) and 52% achieved surgical success for PF (defined as change of at least +3.00). However, preoperative PI (p=0.310) and PF (p=0.054) scores were unable to significantly predict MCID surgical success or failure. Conclusion: After major PTTD reconstruction, PI scores improve to significance but PF scores may not. After PTTD reaches an advanced stage, surgery may provide significant pain relief and improvement in physical function and radiographic parameters, but it may be difficult to predict clinical improvement based solely on preoperative PROMIS scores. Realistic expectations of improvements in pain and functionality should be maintained postoperatively in advanced PTTD surgery.


2018 ◽  
Vol 6 (7_suppl4) ◽  
pp. 2325967118S0010
Author(s):  
Robert Kollmorgen ◽  
Brian Lewis ◽  
Richard C. Mather ◽  
Steven Olson

Objectives: Current Hip Patient Reported Outcome Scores (PROs) are not universally obtained, centers use different forms to try to interpret treatment outcomes, and are limited by floor and ceiling effects. Legacy scores of Modified Harris Hip Score (mHHS), International Hip Outcome Tool (iHOT), and Hip Outcomes Score (HOS) are common place and used in the literature. Patient compliance for legacy PROs have been shown to limit proper data collection. PROMIS measures were developed through NIH funding, vetted against a population norm and PROMIS Computer Adaptive Testing (CAT) has been shown in recent literature to compare well with knee and shoulder legacy scores, and are completed in a quicker amount of time. We hypothesize that in a hip preservation population, the CAT PROMIS Profile V2.0 and PROMIS physical function (PF) would show high correlation with legacy scores of (mHHS, iHOT, and HOS). Methods: After obtaining IRB approval, power analysis revealed 86 patients were needed to detect a significant difference. 100 patients were prospectively enrolled. Patients were asked to complete the iHOT-12, mHHS, HOS and then complete the CAT PROMIS Profile v 2.0. Inclusion criteria for the current study included all Initial encounter and single follow-up patients that have completed the CAT portion and started the legacy scores before opting out. Exclusion criteria will be any patient with a repeat encounter, patients under the age of 18 or a patient that did not complete the legacy or CAT scores. Repeat encounters were excluded due to statistical analysis assuming independence among observers. Correlation between instruments was defined as excellent (>0.7), excellent-good (0.7-0.61), good (0.6-0.4), and poor (0.3-0.2). Results: Demographics of 75 females and 25 males, mean BMI 26.3, and mean age 36.1 (range 18-67). The PROMIS Physical function, Pain Intensity, and Ability to Participate in Social Roles showed excellent correlation with the iHOT-12 (r=0.71 P<0.001), mHHS (r=0.8 P<0.001) and HOS (r=0.82 P<0.001). Patients averaged 21.6 questions to complete all seven arms of the PROMIS Profile. No patient experienced a ceiling effect utilizing the PROMIS Profile CAT. Conclusion: The PROMIS Profile allows for an in-depth look at patients’ dysfunction, not asked in current legacy scores. The PROMIS Physical function and Pain Intensity show excellent correlation with iHOT-12, mHHS and HOS. The CAT PROMIS Profile, shows no observed ceiling effect and can be considered to replace current legacy measures in hip preservation.


Sign in / Sign up

Export Citation Format

Share Document